LIGAND PHARMACEUTICALS INCORPORATED
Asset & Liabilities Breakdown
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
FY2014
FY2013
FY2012
FY2011
FY2010
Asset Breakdown FY2016
Total Assets: $601.6M
Liabilities Breakdown FY2016
Total Liabilities: $230.7M
Asset Breakdown
Total Assets: $601.6M
| Line Item | Value | % of Total |
|---|---|---|
| Cash & Equivalents | $18.8M | 3.1% |
| Accounts Receivable | $14.7M | 2.4% |
| Inventory | $1.9M | 0.3% |
| Property, Plant & Equipment | $1.8M | 0.3% |
| Goodwill | $72.2M | 12.0% |
| Intangible Assets | $204.7M | 34.0% |
| Other Assets | $287.5M | 47.8% |
Liabilities Breakdown
Total Liabilities: $230.7M
| Line Item | Value | % of Total |
|---|---|---|
| Accounts Payable | $2.7M | 1.2% |
| Long-Term Debt | $0 | 0.0% |
| Other Liabilities | $228.0M | 98.8% |